Study S001235

A 24-week, Single Centre, Randomized, Parallel-group, Double-blind, Placebo Controlled Phase II Study With an Optional 28-week Open-label Extension to Evaluate the Efficacy on Body Weight of Dapagliflozin 10 mg Once Daily in Combination With Exenatide 2 mg Once Weekly in Obese Non-diabetic Subjects.

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT02313220
Acronym: Dapalost
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 50
Start: 2014-12
Primary completion: 2016-03
Lead sponsor: Uppsala University
Conditions: Obesity
Interventions: DRUG:Dapagliflozin; DRUG:Exenatide; DRUG:Placebo
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2014-003432-39; NIH:2014

Registered primary outcomes

Body weight (kg) [From randomization to 24 weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.